The blood-based test by Astrin Biosciences shows high sensitivity and specificity across cancer stages and subtypes, ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, ...

—Tumor-informed circulating tumor DNA testing was shown to be highly sensitive for monitoring patients with metastatic breast cancer receiving standard-of-care therapy. Circulating tumor DNA (ctDNA) ...

Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional ...

The optimal approach to treatment in the post-CDK4/6 inhibitor setting remains undefined, but multiple strategies have ...

A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an ...

A new study from researchers at Baylor College of Medicine brings hope for a more personalized approach to treat estrogen receptor-positive (ER+) breast cancer, the most common type of this cancer.

Lobular breast cancer patients gathered at Fred Hutch Cancer Center last week for a two-hour program featuring patient stories, epidemiological findings and new developments in screening and clinical ...

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...